Skip to main content
Evidence Snapshot

5-hydroxytryptamine receptor 2A

CHEMBL3446 SINGLE PROTEIN Bos taurus
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:30:13Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3446
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats 5-hydroxytryptamine receptor 2A as ChEMBL target CHEMBL3446, mapped to UniProt Q75Z89. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
5-hydroxytryptamine receptor 2A
SINGLE PROTEIN · Bos taurus
As of 2026-09-13
ChEMBL target ID
CHEMBL3446
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q75Z89
5-hydroxytryptamine receptor 2A
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why 5-hydroxytryptamine receptor 2A matters

As of 2026-09-13

5-hydroxytryptamine receptor 2A is reviewed as 5-hydroxytryptamine receptor 2A (UniProt Q75Z89); the current evidence base includes 6 approved drugs, 144 compounds, and 17 assays, with lead potency reaching pChEMBL 8.5.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 6 approved drugs, 144 compounds, and 17 assays for this target. The dominant activity type is IC50. CHEMBL42 is the current potency anchor at pChEMBL 8.5.

Use CHEMBL42 as the tractability anchor when discussing potency (pChEMBL 8.5).

Activity source · ChEMBL 36 via Core Engine
6 approved pChEMBL 8.5
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why 5-hydroxytryptamine receptor 2A matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q75Z89, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

144
Total Compounds
17
Total Assays
6
Approved Drugs
IC50: 149.0, KI: 11.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL42
 8.5 IC50 Approved
No preferred name
CHEMBL1729
 8.1 Ki Approved
No preferred name
CHEMBL14376
 8.1 IC50 Approved
No preferred name
CHEMBL37170
 7.8 Ki —
No preferred name
CHEMBL54
 7.5 IC50 Approved

Approved Drugs

Structure Compound First Approval
ILOPERIDONE
CHEMBL14376
 2009
CISAPRIDE
CHEMBL1729
 1993
CLOZAPINE
CHEMBL42
 1989
BUSPIRONE
CHEMBL49
 1986
HALOPERIDOL
CHEMBL54
 1967
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:30:13Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3446